Amorfix to Present at the Rodman & Renshaw 14th Annual Global Investment Conference

TSX: AMF

TORONTO, Aug. 27, 2012 /CNW/ - Amorfix Life Sciences Ltd, a product development company developing therapeutic products and diagnostics for the treatment of misfolded protein diseases, announced today that Dr. Robert Gundel, President and CEO, will present a corporate overview at the Rodman & Renshaw 14^th Annual Global Investment Conference being held in New York City on September 9-12, 2012.  Dr. Gundel will discuss the Company's diagnostic and therapeutic programs aimed at the early diagnosis and treatment of misfolded protein diseases including amyotrophic lateral sclerosis, Alzheimer's disease, and cancer.  The presentation is scheduled for Tuesday, September 11 at 4:05 pm eastern standard time.  The Annual Global Investment Conference is one of the premier meetings for networking of companies and investors.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD and mild cognitive impairment. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life Sciences Ltd.

SOURCE: Amorfix Life Sciences Ltd.

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: [phone]
Fax: [phone]
[email protected]

Janet Clennett
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: [phone]
Fax: [phone]
[email protected]